Cont A2

enhancing polymer and comprises an equivalent quantity of said drug in said solubility-improved form,

said composition not being a dispersion.

A2

30. (Once Amended) A composition comprising:

(a) a drug in a pharmaceutically acceptable solubility-improved form; and

(b) a concentration-enhancing polymer combined with said drug in a sufficient amount so that said composition provides, after introduction to a use environment, a dissolution area under the concentration versus time curve in said use environment for a period of at least 90 minutes during the 1200 minutes immediately following introduction to said use environment that is at least 1.25-fold the corresponding area under the curve provided by a control composition, wherein said control composition is free from said concentration-enhancing polymer and comprises an equivalent quantity of said drug in said solubility-improved form,

said composition not being a dispersion.

A3

58. (Once Amended) A composition comprising:

(a) a drug in a pharmaceutically acceptable solubility-improved form; and

(b) a concentration-enhancing polymer combined with said drug in a sufficient amount so that said composition provides, after introduction to a use environment, a relative bioavailability of at least 1.25,

said composition not being a dispersion.

Sub B1

A4

86. (Once Amended) A method of administering a drug comprising co-administering to a patient in need of said drug:

(a) a drug in a solubility-improved form; and

(b) a concentration-enhancing polymer;

wherein said concentration-enhancing polymer is co-administered with said solubility-improved form in a sufficient amount, so that after introduction to a use environment, a maximum concentration of said drug in said use environment is provided that is at least

1.25-fold an equilibrium concentration of said drug in said use environment provided by a control composition;

cont A4

and wherein a concentration of said drug in said use environment is provided that exceeds said equilibrium concentration for a longer time than the concentration of said drug in said use environment provided by said control composition exceeds said equilibrium concentration;

and wherein said control composition is free from said concentration-enhancing polymer and comprises an equivalent quantity of said drug in said solubility-improved form,

and provided (a) and (b) are not administered in a dispersion.

A5

106. (Once Amended) A method of administering a drug comprising co-administering to a patient in need of said drug:

(a) a drug in a solubility-improved form; and

(b) a concentration-enhancing polymer;

wherein said concentration-enhancing polymer is co-administered with said drug in a sufficient amount so that, after introduction to a use environment, a dissolution area under the concentration versus time curve is provided in said use environment for a period of at least 90 minutes during the 1200 minutes immediately following introduction to said use environment that is at least 1.25-fold the corresponding area under the curve provided by a control composition;

and wherein said control composition is free from said concentration-enhancing polymer and comprises an equivalent quantity of said drug in said solubility-improved form,

and provided (a) and (b) are not administered in a dispersion.

A6

126. (once Amended) A method of administering a drug comprising co-administering to a patient in need of said drug:

(a) a drug in a solubility-improved form; and

(b) a concentration-enhancing polymer;

wherein said concentration-enhancing polymer is co-administered with said drug in a sufficient amount so that, after introduction to a use environment, a relative bioavailability is provided of at least 1.25-fold that of a control composition, wherein said control composition is free from said concentration-enhancing polymer and comprises an equivalent quantity of said drug in said solubility-improved form,

and provided (a) and (b) are not administered in a dispersion.